(.+-.)-cis-2-Methylspiro (1,3-oxathiolane-5,3'-quinuclidine) Hydrochloride, Hemihydrate (SNI-2011, Cevimeline Hydrochloride) Induces Saliva and Tear Secretions in Rats and Mice: The Role of Muscarinic Acetylcholine Receptors.

DOI Web Site Web Site Web Site Web Site View 1 Remaining Hide 17 Citations 48 References
  • Iga Yoshinori
    Research Institute of Life Science, Snow Brand Milk Products Co., Ltd.
  • Arisawa Hirohiko
    Research Institute of Life Science, Snow Brand Milk Products Co., Ltd.
  • Ogane Nobuo
    Research Institute of Life Science, Snow Brand Milk Products Co., Ltd.
  • Saito Yasunari
    Research Institute of Life Science, Snow Brand Milk Products Co., Ltd.
  • Tomizuka Toshie
    Research Institute of Life Science, Snow Brand Milk Products Co., Ltd.
  • Nakagawa-Yagi Yuzo
    Research Institute of Life Science, Snow Brand Milk Products Co., Ltd.
  • Masunaga Hiroaki
    Research Institute of Life Science, Snow Brand Milk Products Co., Ltd.
  • Yasuda Hiroshi
    Research Institute of Life Science, Snow Brand Milk Products Co., Ltd.
  • Miyata Nobuo
    Research Institute of Life Science, Snow Brand Milk Products Co., Ltd.

Bibliographic Information

Other Title
  • (±)-cis-2-Methylspiro[1,3-oxathiolane-5,3′-quinuclidine] Hydrochloride, Hemihydrate(SNI-2011, Cevimeline Hydrochloride) Induces Saliva and Tear Secretions in Rats and Mice:The Role of Muscarinic Acetylcholine Receptors
  • プラスマイナス cis 2 Methylspiro 1 3 oxathiola
  • (±)-cis-2-Methylspiro[1,3-oxathiolane-5,3-quinuclidine] Hydrochloride, Hemihydrate (SNI-2011, Cevimeline Hydrochloride) Induces Saliva and Tear Secretions in Rats and Mice: The Role of Muscarinic Acetylcholine Receptors

Search this article

Abstract

We investigated effects of (±)-cis-2-methylspiro[1, 3-oxathiolane-5, 3′-quinuclidine] hydrochlo- ride, hemihydrate (SNI-2011, cevimeline hydrochloride), a rigid analogue of acetylcholine, on saliva and tear secretions in rats and mice to evaluate its therapeutical efficacy for xerostomia and xerophthalmia in patients with Sjögren’s syndrome and X-ray exposure in the head and neck. Intraduodenal administrations of SNI-2011 increased saliva secretion in a dose-dependent manner at doses ranging from 3 to 30 mg/kg in normal rats and mice, two strains of autoimmune disease mice and X-irradiated saliva secretion defective rats. The salivation elicited by SNI-2011 was completely inhibited by atropine. A similar atropine-sensitive response was observed in tear secretion. In rat submandibular/sublingual gland membranes, [3H]quinuclidinyl benzilate (QNB) binding was saturable, and Scatchard plot analysis revealed a single population of binding sites with a Kd of 22 pM and a maximal binding capacity of 60 fmol/mg protein. The competitive inhibition curve of the [3H]QNB binding by SNI-2011 was obtained, and its dissociation constant value calculated from IC50 was 1 - 2 μM. These results suggest that SNI-2011 increases saliva and tear secretions through a direct stimulation to muscarinic receptors in salivary and lacrimal glands, and they suggest that SNI-2011 should be beneficial to patients with Sjögren’s syndrome and X-ray exposure in the head and neck.

Journal

Citations (17)*help

See more

References(48)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top